You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,814,721


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,814,721
Title:Use of inhibitors of bruton'S tyrosine kinase (BTK)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (San Jose, CA), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:15/066,491
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,814,721
Patent Claims: 1. A method for treating marginal zone lymphoma (MZL) in an individual in need thereof, wherein the individual has received at least one prior anti-CD20-based therapy, comprising: administering to the individual once per day about 560 mg of an oral dose of a compound having the structure: ##STR00046##

2. The method of claim 1, wherein the MZL is relapsed or refractory MZL.

3. The method of claim 1, wherein the MZL is extranodal marginal zone B cell lymphoma.

4. The method of claim 1, wherein the MZL is extranodal marginal zone B-cell lymphoma-mucosa-associated lymphoid tissue (MALT) lymphoma.

5. The method of claim 1, wherein the MZL is nodal marginal zone B-cell lymphoma.

6. The method of claim 1, wherein the MZL is splenic marginal zone B-cell lymphoma.

7. The method of claim 1, wherein the compound is in the form of a solid oral dosage form.

8. The method of claim 1, wherein, following administration of the compound, the individual achieves a stable disease, a partial response, or a complete response.

9. The method of claim 1, wherein, following administration of the compound, the individual achieves a partial response or a complete response.

10. The method of claim 1, wherein, following administration of the compound, the individual achieves a complete response.

11. The method of claim 1, wherein, following administration of the compound, the individual does not experience a progressive disease.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.